EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants

Bridget L Morse, Shobha Bhattachar, Xiaosu Ma, David E Coutant, Boris Czeskis, Clare Nicoll, Kenneth C Cassidy

Clinical Pharmacology in Drug Development · 2026-01 · 15 (1)

DOI: 10.1002/cpdd.1594 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025-09. Verfasst von Bridget L Morse und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, IN, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Orforglipron is a non‐peptide, oral glucagon‐like peptide 1 receptor agonist under development for glycemic control in adults with type 2 diabetes and weight management in people with obesity. Two phase 1, open‐label studies evaluated the disposition and absolute bioavailability of orforglipron in healthy adults. Study A participants (N = 10) received a 1‐mg orforglipron oral capsule while fasting and an intravenous dose of ∼21 µg of [14C]‐orforglipron. Study B participants (N = 6) received an oral solution of 3 mg of orforglipron with ∼200 µCi of [14C]‐orforglipron while fasting. In study A, total plasma radioactivity and [14C]‐orforglipron were measured by accelerator mass spectrometry (AMS) and high‐performance liquid chromatography (HPLC)/AMS, while orforglipron was measured by HPLC/MS. The mean absolute oral bioavailability of orforglipron was 79.1% ± 16.8%. In study B, urine and feces were analyzed for total radioactivity. Metabolic radioprofiling was performed on selected plasma and fecal samples by HPLC/high‐resolution MS. The primary route of elimination for [14C]‐orforglipron‐related radioactivity was via the feces (87% ± 2.8%) with minimal urinary excretion (0.2% ± 0.02%). Total recovery of administered radioactivity was 88% over 384 hours after the dose. Metabolite profiling from study B showed that orforglipron underwent extensive oxidative metabolism, followed by microbial metabolism of the oxadiazolone ring. Orforglipron was the most abundant plasma component (93.3%) with minor oxidative metabolites M7 (3.3%) and M23 (1.6%).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HumansMaleBiological AvailabilityAdultAdministration, OralFemaleHealthy VolunteersYoung AdultMiddle AgedGlucagon-Like Peptide-1 Receptor AgonistsOxadiazolesFluorine Compounds

Stichwörter der Autor:innen

GLP‐1 receptor agonistabsolute bioavailabilityaccelerator mass spectrometrymass balanceobesityorforglipronpharmacokineticstype 2 diabetes

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsorforglipronOxadiazolesFluorine Compounds

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, IN, USA.

Zitieren

APA

Morse, B. L., Bhattachar, S., Ma, X., Coutant, D. E., Czeskis, B., Nicoll, C., & Cassidy, K. C. (2026). Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. Clinical Pharmacology in Drug Development, 15(1). https://doi.org/10.1002/cpdd.1594

Vancouver

Morse BL, Bhattachar S, Ma X, Coutant DE, Czeskis B, Nicoll C, et al. Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. Clinical Pharmacology in Drug Development. 2026;15(1). doi:10.1002/cpdd.1594

BibTeX
@article{Morse2026,
  author = {Morse, Bridget L and Bhattachar, Shobha and Ma, Xiaosu and Coutant, David E and Czeskis, Boris and Nicoll, Clare and Cassidy, Kenneth C},
  title = {Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {1},
  doi = {10.1002/cpdd.1594}
}
Kostenlos starten →